Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/06/25
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research • 11/05/25
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial GuidancePRNewsWire • 11/05/25
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to DeclineZacks Investment Research • 10/29/25
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025PRNewsWire • 10/22/25
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast CancerBusiness Wire • 10/21/25
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPRNewsWire • 10/02/25
Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY RatingSeeking Alpha • 09/24/25
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych CongressesPRNewsWire • 09/22/25
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse GliomaPRNewsWire • 09/09/25
Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/03/25
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare ConferencePRNewsWire • 08/21/25
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025PRNewsWire • 08/20/25
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355PRNewsWire • 08/20/25
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the StockZacks Investment Research • 08/08/25
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline GliomaPRNewsWire • 08/06/25
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View CutZacks Investment Research • 08/06/25